Grand Pharma H1 FY26 profit attributable to owners falls 11.01% to HK$1.06 billion; revenue rises 3.2% to HK$6.39 billion

• Grand Pharmaceutical Group reported first-half revenue of HK$6.39 billion, up 3.2% year over year.
• Profit attributable to owners fell 11% to HK$1.06 billion, with Telix fair-value and disposal gains of HK$88.78 million.
• Adjusted net operating profit attributable to owners, excluding Telix investment impacts, declined 6.63% to HK$972.76 million.
• Nuclear medicine anti-tumor diagnosis and treatment segment revenue jumped 55.4% to HK$655.24 million on higher clinical demand and new-product scaling.
• Pipeline updates included NMPA acceptance of TLX591-CDx NDA, NMPA commercialization clearance for TP-03, and FDA fast-track for GPN01530-2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12301157), on August 26, 2026, and is solely responsible for the information contained therein.